SDM-RCC: A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)

Sponsor
St. Antonius Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05548621
Collaborator
Merck Sharp & Dohme LLC (Industry)
260
25

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the effect of two decision aids for renal cell carcinoma (RCC) on the decision-making process and the quality of the decision.

Condition or Disease Intervention/Treatment Phase
  • Other: Decision aid

Detailed Description

Background: Treatment options for patients diagnosed with RCC depend on the stage of the disease, histopathology and patient's preferences and values regarding outcomes. For local (non-metastatic) disease, gold standard for treatment is surgical resection of the tumour. Besides this, ablative therapies or active surveillance could also be an option. For metastatic disease, targeted therapy and/or immunotherapy can be offered and new treatment options are being tested in clinical trials. The number of available treatment options for patients with RCC is increasing, but the availability of these options differs per hospital and the transparency about treatment options is limited, resulting in practice variation between hospitals.

Decision aids help patients to make decisions regarding treatment, particularly when there is not one medically superior treatment option. In this tools treatment options are explained, including outcome information such as possible side effects and benefits of therapy. Decision aids have proven to lead to increased patient knowledge, less anxiety in patients, improved health outcomes such as physical en mental health, reductions in unwarranted variation in care and costs, greater alignment of care with patients' values.

For patients with RCC, two decision aids are in development right now: one decision aid focussed on local disease and one decision aid focussed on metastatic disease. Using these decision aids, patients are encouraged to make a well-informed decision together with the healthcare professional.

Objective: To assess how the decision aids for RCC influence the quality of the decision-making processes for RCC, defined as the extent to which elements of shared decision-making (SDM) are observed.

Design, setting and participants: This study includes patients clinically diagnosed with RCC, facing a decision which is addressed in the decision aids. Study design will be a prospective multicenter pre-test post-test study.

Outcome measurements and statistical analysis: The primary endpoint of this study is the mean change in OPTION-5 score between pre-test and post-test groups. Secondary outcome measures include perceived quality of the decision-making process, quality of the decision and implementation of the decision aids.

Study Design

Study Type:
Observational
Anticipated Enrollment :
260 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Pre-test

Patients with RCC receiving usual care (without use of the decision aids)

Post-test

Patients with RCC using the decision aids

Other: Decision aid
Online interactive decision aid for RCC

Outcome Measures

Primary Outcome Measures

  1. OPTION-5 [During consultation]

    Observed patient involvement in decision-making

Secondary Outcome Measures

  1. Decisional conflict scale [Two weeks and nine weeks after consultation]

    Validated scale to measure personal perceptions of uncertainty in choosing options, modifiable factors contributing to uncertainty and effective decision making.

  2. Preparation for decision-making [Two weeks after consultation]

    Validated scale that assesses the patient's perception of how useful a decision aid is in preparing the respondent to communicate with their practitioner at a consultation visit and making a health decision.

  3. Control preference scale [Two weeks after consultation]

    Validated measure of patient's preferred and actual roles in treatment decisions

  4. SDM-Q-9 [Health care professional: directly after consultatiion, patient: two weeks after consultation]

    Validated questionnaire of perceived level of shared decision-making

  5. Knowledge check [Two weeks after consultation]

    Objective assessment of patient's understanding of information relevant for the decision at stake using ten questions which can be answered as true/false/I don't know.

  6. Implementation of the decision aids [Nine weeks after consultation]

    Qualitative information about experiences with implementation and use of the decision aids will be obtained through semi-structured interviews with patients and healthcare professionals.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients clinically diagnosed with RCC

  • Patients facing a decision which is addressed in the decision aids (T1 tumor or metastatic disease)

  • Written informed consent

Exclusion Criteria:
  • Patients who are not able to fill in a questionnaire or undergo an interview individually

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • St. Antonius Hospital
  • Merck Sharp & Dohme LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cato Bresser, Coordinating Investigator, St. Antonius Hospital
ClinicalTrials.gov Identifier:
NCT05548621
Other Study ID Numbers:
  • WW 22.121/NWMO22.06.013
First Posted:
Sep 21, 2022
Last Update Posted:
Sep 21, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Cato Bresser, Coordinating Investigator, St. Antonius Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2022